RxDoctor Payments Data

Minnette Williams, MD

Cardiovascular Disease · Riverdale, GANPI 1376768259

Payments from drug & device makers

$1,044in general payments, 2019–2025

Across 43 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$428
  • Pfizer$139
  • Amgen$127
  • Boston Scientific$102
  • Cardiva Medical, Inc.$88
  • AstraZeneca$34
  • plus $125 from 6 others

What the payments were for

  • Food & beverage$1,03899%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,044 in reported general payments places this provider in the 30th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$165,670
Medicare patients
506
Services billed
3,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban380$369,779
XareltoRivaroxaban126$119,348
EntrestoSacubitril/Valsartan53$57,213
MultaqDronedarone Hcl25$24,363
JardianceEmpagliflozin22$20,125
Metoprolol Succinate386$4,534
Carvedilol275$2,029
Amiodarone Hcl64$1,921
Flecainide Acetate41$1,758
Atorvastatin Calcium168$1,676
SotalolSotalol Hcl97$1,544
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$1,391
Pravastatin Sodium41$859
Potassium Chloride69$848
Furosemide187$791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$139$369,779380 claims
NovartisEntresto$22$57,21353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Riverdale

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →